SubHero Banner
Text

Keytruda® (pembrolizumab) – New warning

November 29, 2017 – The FDA approved an update to the Warnings and Precautions section of the Keytruda (pembrolizumab) drug label regarding increased mortality in patients with multiple myeloma (MM) when Keytruda is added to a thalidomide analogue and dexamethasone.

Download PDF